|Yes, I understand the recall is independent of the trial. But as you say a Cluster F and one that in my view must be closely related to the departure of the device division CEO. Ie is all well at head office? It is simply another incident that does not inspire confidence in a management that has already been sanctioned by the OSC. I think the medical division science is so complex, requires very specific skill sets and has such incredibly good scientists on board it is harder for bad management to interfere.|
Tlt has stated Europe has been dropped in favour of just Canada and U.S..
The sooner the U.S. gets underway the sooner TLT has access to 10x the possible trial participants and the more TLT becomes attractive to U.S. investors.
I too continue to be encouraged by Phase 1 trial results and can only imagine phase 2 trial will have minor procedural improvements that will benefit the process and we shall see if the double dose also improves results.